Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Marstacimab Long-Term Extension in Severe Hemophilia
NCT03363321Phase 2Completed
- Sponsor
- Pfizer
- Start
- May 2018
- Primary completion
- Aug 2020
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 2, open-label trial of marstacimab in hemophilia A and hemophilia B (HB) (6 cohorts), sponsored by Pfizer. Primary endpoints: Number of Participants With Treatment-Emergent Adverse Events, Number of Participants With Abnormal Laboratory Findings and 4 more. Started May 2018; status: completed.
02
Drugs
marstacimab
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on NCT03363321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03363321.